Payment overview · 2025
General Payments
$115.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Harpreet Singh, MD
Allopathic & Osteopathic Physicians|Family Medicine · MISSION HILLS, CA · NPI 1881805745
Verified facts
What the public records show
CMS Open Payments records show Harpreet Singh, MD received $115.00 in general payments during 2025 across 1 reported records.
Regeneron Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $115.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $115.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 473 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 33 |
| Omeprazole | Omeprazole | 182 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 172 | 37 |
| Metformin Hcl | Metformin Hcl | 170 | 37 |
| Losartan Potassium | Losartan Potassium | 155 | 34 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 137 | 16 |
| Montelukast Sodium | Montelukast Sodium | 135 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 104 | 25 |
| Carvedilol | Carvedilol | 98 | 16 |
| Gabapentin | Gabapentin | 94 | 36 |
| Famotidine | Famotidine | 85 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 33 |
| Meloxicam | Meloxicam | 84 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 36 |
| Enulose | Lactulose | 82 | suppressed |
| Eliquis | Apixaban | 80 | 16 |
| Januvia | Sitagliptin Phosphate | 76 | 17 |
| Finasteride | Finasteride | 75 | 17 |
| Simvastatin | Simvastatin | 72 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 64 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 20 |
| Glipizide | Glipizide | 63 | 14 |
| Lisinopril | Lisinopril | 61 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 60 | 11 |
| Alprazolam | Alprazolam | 58 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 21 |
| Glimepiride | Glimepiride | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 53 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | suppressed |
| Linzess | Linaclotide | 48 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 12 |
| Ketoconazole | Ketoconazole | 46 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 45 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 43 | suppressed |
| Myrbetriq | Mirabegron | 42 | 13 |
| Tradjenta | Linagliptin | 42 | suppressed |
| Atenolol | Atenolol | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 36 |
| Allopurinol | Allopurinol | 36 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | 15 |
| Rybelsus | Semaglutide | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 30 | suppressed |
| Furosemide | Furosemide | 29 | suppressed |
| Prednisone | Prednisone | 29 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Lactulose | Lactulose | 26 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Dexamethasone | Dexamethasone | 23 | 21 |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Constulose | Lactulose | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 17 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $115.00 · 1 records | Regeneron Pharmaceuticals, Inc. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error